Celcuity Inc. (CELC) Discusses FDA Approval of REVTORPYK

Celcuity Inc. (CELC) Discusses FDA Approval of REVTORPYK for Advanced HR+/HER2- Breast Cancer and Commercial Launch Plans July 14, 2026 5:30 PM EDTCompany...

Celcuity Inc. (CELC) Discusses FDA Approval of REVTORPYK for Advanced HR+/HER2- Breast Cancer and Commercial Launch Plans July 14, 2026 5:30 PM EDT Company Participants Jodi Sievers - Head of Investor Relations & Corporate Communications Brian Sullivan - Co-Founder, Chairman & CEO Igor Gorbatchevsky - Chief Medical Officer Eldon Mayer - Chief Commercial Officer Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Bradley Canino - Guggenheim Securities, LLC, Research Division Silvan Tuerkcan - Citizens JMP Securities, LLC, Research Division Eva Fortea-Verdejo - Wells Fargo Securities, LLC, Research Division Oliver McCammon - LifeSci Capital, LLC, Research Division Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Hello, and welcome to Celcuity conference call.

[Operator Instructions] I would now like to hand the conference over to Jodi Sievers, Head of Investor Relations and Corporate Communications. You may begin. Jodi Sievers Head of Investor Relations & Corporate Communications Thank you, operator.

Good day, everyone, and thank you for joining us today to discuss FDA approval of gedatolisib. Today's press release, U.S. prescribing information and the slides we'll be reviewing today are available on our website, celcuity.com. Before we begin, I must point out that there, some of our comments today contain forward-looking statements that are subject to risks, uncertainties and assumptions.

In particular, our expectations around gedatolisib are uncertain and subject to change. Should our expectations fail to materialize or should our assumptions prove to be incorrect, actual company results could differ materially from these forward-looking statements. A description of the risks, uncertainties and assumptions is included in our SEC filings.

With that, I will turn the call over to Brian Sullivan, Co-Founder and Chief Executive Officer of Celcuity. Brian? Brian Sullivan Co-Founder, Chairman & CEO Thank

Why this matters locally

This business story matters locally because it may affect readers, businesses, commuters, families, or public services in British Columbia.

Local impact

BC Post links this item to British Columbia coverage so readers can follow related city updates, weather, traffic, events, and category news in one place.

Timeline